Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Cytodyn

Cytodyn

Cytodyn is a company that develops treatments and therapies for people with infections and immune deficiency viruses

Cytodyn is a company that develops treatments and therapies for people with infections and immune deficiency viruses. The company was founded in 2002 in Lake Oswego, Oregon, United States.

The company is primarily interested in creating products and solutions to impact HIV and AIDS issues. The company's main pursuit is to develop a monoclonal antibody receptor antagonist that help prevent HIV, GVHD, NASH, and cancer from metastasizing on and using the CCR5 receptors as a gateway to healthy cells. The antibody is known as Leronlimab.

COVID-19

The company has began developing solutions in response to the outbreak of COVID-19. The company has began protocol for a Phase 2 clinical trial for the treatment of patients with the coronavirus through the use of Leronlimab. The company believes that the virus can progress into pneumonia and eventually death due to acute respiratory distress syndrome.

The treatments with Leronlimab that Cytodyn has developed have been approved as a therapy for patients who experience respiratory issues as a result of the coronavirus disease. Leronlimab has a resonse against pathogen in the areas of inflammation and the migration of macrophages and the release of cytokines (what causes the damage in the lungs of certain patients). The company believes that the use of Leronlimab will reduce the morbdity and mortality of severe cases of COVID-19. Cytodyn has partnered with IncellDx to develop a suite of diagnostics to monitor the effects of the monoclonal antibody receptors.

Timeline

August 12, 2013
Cytodyn raises a $1,200,000 seed round.

Funding rounds

Patents

Further Resources

Title
Author
Link
Type
Date

CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)

Web

March 9, 2020

CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140)

Web

March 8, 2020

News

Title
Author
Date
Publisher
Description
Annalee Armstrong
September 24, 2021
FierceBiotech
If CytoDyn's management can't get their lead treatment approved, a group of very optimistic investors want to give it a try. After weeks of very public infighting at the Vancouver, Washington-based biotech, a stockholder group has come forward with a strategic plan to get leronlimab approved in a cancer indication.
Annalee Armstrong
August 13, 2021
FierceBiotech
CytoDyn's efforts to get leronlimab past the regulatory finish line in any indication has been a saga--including an incident in which the biotech sent the wrong data sets to the FDA. But now, the regulator seems to have pointed the biotech in the right direction for a filing for approval in HIV. In a brief update Friday morning, CytoDyn disclosed that the FDA has sent over some comments on the company's recently resubmitted dose justification report.
Annalee Armstrong
August 3, 2021
FierceBiotech
The blows keep coming for CytoDyn. After the FDA blasted the company for pumping up their unapproved and unproven COVID-19 therapeutic, the Department of Justice and the Securities and Exchange Commission is now subpoenaing the company and its executives. Two investigations were disclosed in an SEC filing dated July 30.
Annalee Armstrong
May 18, 2021
FierceBiotech
CytoDyn President and CEO Nader Pourhassan begged his investors to stop trashing the FDA after the agency issued a rare public rebuke over the company's public statements on a pair of failed COVID-19 clinical trials. "You can throw all kinds of eggs and tomatoes, whatever you like, at me. I deserve it," Pourhassen said. "But please don't do that to the regulatory agency."
Mark Terry
May 18, 2021
BioSpace
The U.S. FDA scolded CytoDyn of misrepresenting its clinical trial results for Leronlimab in COVID-19.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.